Skip to main content

Formulate

Find pharma jobs. Prep for interviews like no one else can.

Browse

Jobs Companies Drugs Indications Career Advisor About

Insider Intel

Intelligence Hub Therapeutic Areas Contribute Intro Network Salary Explorer For Employers

Legal

Privacy Policy Terms of Service About Our Crawler Content Removal Your Privacy Choices

© 2026 Formulate. Pharma Jobs with Drug Intelligence.

Sanaria - Jobs & Pipeline | Formulate

Companies
Sanaria

Sanaria

MD - RockvilleBiotechnology

Website LinkedIn Careers Page

Focus: Sanaria is a specialized biotech focused on malaria vaccines and research reagents, headquartered in Rockville, MD with a narrow therapeutic focus on infectious diseases.

Infectious Diseases Vaccines

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

0

About Sanaria

AI assessmentNot Hiring

No open roles listed right now. Follow Sanaria to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

40 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Plasmodium falciparum sporozoites 2sites

N/A

Clinical Trials (1)

NCT01465048Optimisation of Controlled Human Malaria Infection Using Sporozoites Administered by Needle and Syringe

N/A

Help build intelligence for Sanaria

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Mission-driven work on malaria vaccines addressing a global health priority with no commercial competitors in direct competition
Active clinical pipeline with 20 ongoing trials demonstrates continuous research momentum and advancement in vaccine development
Specialized expertise in Plasmodium falciparum sporozoite (PfSPZ) technology platform creates differentiated technical skill development

Watch Out For

No open job positions currently available, indicating either full staffing or limited hiring capacity that may constrain career mobility
Pre-revenue biotech status with no disclosed funding or financials raises sustainability questions and limits upside equity potential
Early-stage pipeline (majority Phase 1) with 0 Phase 3 programs means regulatory approval and commercialization remain years away

Generated by Claude from Sanaria's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

PfSPZ Challenge

N/A

Clinical Trials (1)

NCT03496454Susceptibility of Gambian Adults to PfSPZ-Challenge Infection in the Controlled Human Malaria Infection Model

N/A

PfSPZ Vaccine

Phase 1

Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet

Malaria,Falciparum

Phase 1

PfSPZ Vaccine

Phase 1

Clinical Trials (1)

NCT02132299Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian Adults

Phase 1

PfSPZ-LARC2 Vaccine

Malaria Falciparum

Phase 1

Clinical Trials (1)

NCT06652737Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso

Phase 1

PfSPZ Vaccine

Phase 1

Clinical Trials (1)

NCT03420053Study to Evaluate Safety, Immunogenicity and Efficacy of PfSPZ Vaccine in HIV Negative and HIV Positive Tanzanian Adults

Phase 1

PfSPZ Vaccine

Phase 1

Clinical Trials (1)

NCT03510481Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali

Phase 1

MMV390048

Malaria,Falciparum

Phase 1

Clinical Trials (1)

NCT03195387Chemoprotective Activity of MMV390048 in PfSPZ Challenge Model

Phase 1

PfSPZ Vaccine

Phase 1

Clinical Trials (1)

NCT05604521A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI

Phase 1

PfSPZ Challenge

Phase 1

Clinical Trials (1)

NCT01771848Optimization of Controlled Human Malarial Infection by Injection of P. Falciparum Sporozoites in Non-Immune Adults

Phase 1

PfSPZ Challenge

Phase 1

Clinical Trials (1)

NCT01624961Controlled Human Malarial Infection by Intravenous Injection of Plasmodium Falciparum Sporozoites in Non-Immune Adults

Phase 1

Plasmodium falciparum Sporozoite

Plasmodium Falciparum

Phase 1

Clinical Trials (1)

NCT01001650Clinical Trial of the PfSPZ Vaccine

Phase 1

PfSPZ Challenge

Plasmodium Falciparum Malaria

Phase 1

Clinical Trials (1)

NCT02237586Effect of Plasmodium Falciparum Exposure and Sickle Cell Trait on Infection Rates and Kinetics After IV Administration of PfSPZ Challenge

Phase 1

PfSPZ

Phase 1

Clinical Trials (1)

NCT01441167Experimental PfSPZ Vaccine in Adults Without Malaria

Phase 1

PfSPZ Vaccine

Phase 1

P218

Phase 1

Clinical Trials (1)

NCT03707041Safety, Tolerability and Chemoprotective Activity of P218 in PfSPZ Challenge Model

Phase 1

PfSPZ Challenge

Phase 1

Clinical Trials (1)

NCT01728701Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis

Phase 1

Chloroquine Phosphate

Phase 1

Clinical Trials (1)

NCT03083847Dose Escalation PfSPZ-CVac

Phase 1

PfSPZ Challenge

Phase 1

Clinical Trials (1)

NCT01086917Experimental Human Malaria Infection by PfSPZ

Phase 1

PfSPZ Challenge

Phase 1

Clinical Trials (1)

NCT01540903Controlled Human Malaria Infection by Intradermal Injection of Plasmodium Falciparum Sporozoites in Tanzanian Adults

Phase 1

PfSPZ Vaccine

Phase 1

PfSPZ Vaccine

Phase 1

Clinical Trials (1)

NCT02704533Sequential Optimization of Dose and Schedule of PfSPZ Vaccine

Phase 1

PfSPZ Challenge

Phase 1

Clinical Trials (1)

NCT02115516Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chemoprophylaxis

Phase 1

PfSPZ Vaccine

Phase 1

Clinical Trials (1)

NCT02215707A Clinical Trial of the PfSPZ Vaccine Administered by Direct Venous Inoculation in Healthy Malaria-Naïve Adults: Heterologous vs. Homologous Controlled Human Malaria Infection and Reduction in Number of Doses

Phase 1

PfSPZ-GA1 Vaccine

Phase 1

Clinical Trials (1)

NCT03163121Safety and Protective Efficacy of Genetically Attenuated PfSPZ-GA1 Vaccine in Healthy Dutch Volunteers

Phase 1

PfSPZ Vaccine

Phase 1

Clinical Trials (1)

NCT01988636Study of Safety and Effectiveness of Intravenous Immunization With PfSPZ Vaccine in Healthy African Adults

Phase 1

atovaquone/proguanil 250mg/100mg

Phase 1

Clinical Trials (1)

NCT02858817Safety and Protective Efficacy of IV Immunization With Cryopreserved PfSPZ Under A/P Chemoprophylaxis

Phase 1

Normal Saline

Malaria Falciparum

Phase 1

Clinical Trials (1)

NCT06862453Safety, Tolerability and Efficacy Against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria-naïve Adults

Phase 1

PfSPZ Vaccine

Phase 1

Clinical Trials (1)

NCT04966871Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults

Phase 1

PfSPZ Vaccine

Phase 1

Plasmodium falciparum sporozoite

Phase 1

Clinical Trials (1)

NCT02739763Controlled Human Malaria Infection in Semi-Immune Kenyan Adults. (CHMI-SIKA)

Phase 1

Pyronaridine Tetraphosphate, Artesunate Drug Combination

Phase 1/2

Clinical Trials (1)

NCT05441410Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults

Phase 1/2

PfSPZ Vaccine

Phase 1/2

Clinical Trials (1)

NCT02687373Safety, Tolerability and Efficacy of PfSPZ Vaccine in Healthy Children and Infants 5 Months - 9 Years Living in Kenya

Phase 1/2

PfSPZ Challenge

Malaria,Falciparum

Phase 1/2

Clinical Trials (1)

NCT04280692Controlled Human Malaria Infection Transmission Model - Phase A

Phase 1/2

PfSPZ Vaccine

Phase 2

Clinical Trials (1)

NCT03503058Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria

Phase 2

PfSPZ Vaccine

Phase 2

Clinical Trials (1)

NCT03521973Safety, Tolerability and Protective Efficacy of PfSPZ Vaccine in Gabonese Children

Phase 2

Genetically attenuated PfSPZ Vaccine

Malaria (Plasmodium Falciparum)

Phase 2

Clinical Trials (1)

NCT07385287Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults

Phase 2

Sanaria® PfSPZ Vaccine

Phase 2

Clinical Trials (1)

NCT04940130PfSPZ Vaccine Trial in Malian Children

Phase 2

PfSPZ Vaccine

Phase 2

Clinical Trials (1)

NCT02601716PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 35 clinical trials

Top TAs: Infectious Diseases

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Infectious Diseases

34 pipeline

Marketed

Pipeline